NRSN Stock Forecast & Price Target

NeuroSense Therapeutics is attractive because PrimeC has already delivered de-risking clinical evidence in ALS, including favorable safety, statistically significant reductions in TDP-43, a 7.92-point ALSFRS-R advantage at month 18, and a 36.3-month median survival versus 21.4 months with placebo crossover. Its multi-target design is compelling because it tackles shared neurodegenerative mechanisms—neuroinflammation, autophagy impairment, miRNA dysregulation, and iron dyshomeostasis—while early AD biomarker signals in 2Q26 suggest the platform may extend beyond ALS. The investment case is further strengthened by a capital-efficient regulatory strategy, with FDA-cleared Phase 3 PARAGON and a potential Canada filing in 4Q26, though limited cash and financing risk remain the main constraints.

NeuroSense Therapeutics is a highly speculative clinical-stage biotech with no approved product, and its 1H26 EPS of ($2.06) alongside just $0.2 million in cash underscores a severely strained balance sheet and ongoing dependence on external funding. Its lead candidate PrimeC may be differentiated, but the investment case is weakened by the high probability of clinical, regulatory, and commercial setbacks in ALS and other neurodegenerative diseases, where FDA review, trial failure, competition, and payer adoption remain major hurdles. The outlook is further pressured by two Nasdaq deficiencies, including a sub-$1.00 bid price and MVSL below $35 million, both with a September 29, 2026 cure deadline, because delisting risk could impair access to capital needed to fund the pivotal ALS trial.